Amgen
Corporate Headquarters
One Amgen Center Drive
Thousand Oaks
California
91320-1799
United States
Tel: 805-447-1000
Fax: 805-447-1010
Website: http://www.amgen.com/
Email: talentacquisitioninquiries@amgen.com
About Amgen
At Amgen, our mission—to serve patients—drives all that we do. This sense of shared purpose has allowed us to become one of the world’s leading biotechnology companies as we continue to launch new medicines at unprecedented rates and reach millions of patients worldwide.
We collaborate with world-class talent, utilize the industry’s largest toolkit of modalities, and leverage industry-leading partnerships and state-of-the-art technology to develop new processes and products that can turn the tide of serious, life-interrupting illnesses.
As a values-based organization, we aim to make a positive impact on the world. From investments in education to inspire future generations of scientists, to rewarding our colleagues with robust family-centered benefits, we believe in making a difference in the lives of our patients, staff and communities.
At Amgen, we believe in the power of tomorrow and it shows.
Discover what Amgen can do for you by visiting careers.amgen.com.
For more information, visit
www.amgen.com, LinkedIn and follow us on www.twitter.com/amgencareers.
FOLLOW AMGEN:
Tweets by Amgen
The Amgen Difference
1951 articles with Amgen
-
Toronto Innovation Acceleration Partners Announces Strategic Partnership with Amgen
9/9/2019
Toronto Innovation Acceleration Partners, a leading member-based Canadian provider of venture builder expertise in the early-stage health science field, is pleased to announce the establishment of a collaboration with Amgen, a global leader in the biotechnology industry.
-
Amgen shares dropped 4.2% in pre-market trading at good but not amazing results in an early-stage trial of AMG 510 in in patients with previously treated KRAS G12C-mutated solid tumors.
-
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019
9/8/2019
Amgen announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors.
-
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS G12C Inhibitor In Larger Patient Group At WCLC 2019
9/8/2019
Amgen announced new data from the ongoing Phase 1 study evaluating AMG 510 in patients with previously treated KRAS G12C-mutated solid tumors.
-
Amgen To Present At The Morgan Stanley Global Healthcare Conference on Sept. 10, 2019
9/5/2019
Amgen will present at the Morgan Stanley Global Healthcare Conference at 9:10 a.m. ET on Tuesday, Sept. 10, 2019, in New York City.
-
Amgen To Webcast Investor Call At IASLC 2019 World Conference on Lung Cancer
9/4/2019
Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the International Association for the Study of Lung Cancer (IASLC) 2019 World Conference on Lung Cancer (WCLC) on Sunday, Sept. 8, at 8 a.m. PT. David M. Reese, M.D., executive vice president of Research and Development at Amgen,
-
In an ongoing battle between Regeneron Pharmaceuticals and Sanofi versus Amgen over PCSK9 inhibitors to treat high cholesterol, a U.S. district court invalidated Amgen’s patents for Repatha.
-
U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9
8/28/2019
Court rules in favor of Regeneron and Sanofi in ongoing Praluent® (alirocumab) patent litigation
-
New Amgen Data To Be Presented At ESC Congress 2019 Highlight Additional Evidence For Repatha® (Evolocumab) Effectiveness In Cardiovascular Disease Across Multiple Patient Groups
8/28/2019
Amgen (NASDAQ: AMGN) today announced the presentation of 14 cardiovascular scientific research abstracts, including studies evaluating the safety and efficacy of Repatha® (evolocumab) by race and ethnicity and further examining its clinical benefit in patients with familial hypercholesterolemia (FH)
-
Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion
8/26/2019
Bristol-Myers Squibb Company announced that Celgene Corporation, in connection with its merger agreement with Bristol-Myers Squibb, has entered into an agreement with Amgen under which Amgen would acquire the global rights to OTEZLA® for $13.4 billion in cash.
-
Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits
8/26/2019
Amgen announced that it has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers Squibb Company to acquire worldwide rights to Otezla®, the only oral, non-biologic treatment for psoriasis and psoriatic arthritis, and certain related assets and liabilities, for $13.4 billion in cash, or approximately $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits.
-
BMS and Celgene first announced the probable sale of the asset earlier this summer as a means to smooth out the anti-trust review process of the merger from the Federal Trade Commission.
-
In a head-to-head study, BeyondSpring’s plinabulin stood up to Amgen’s Neulasta (pegfilgrastim) in a quality of life study to prevent neutropenia, a common side effect for chemotherapy patients.
-
Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)
8/22/2019
Study Evaluated Efficacy and Safety of ABP 798 Compared to Rituxan in Patients With Non-Hodgkin's Lymphoma
-
Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.
-
Amgen Wins Patent Case On Enbrel® (etanercept)
8/9/2019
Amgen (NASDAQ:AMGN) today announced that the U.S. District Court for the District of New Jersey has ruled in Amgen's favor on validity of the two patents that describe and claim Enbrel® (etanercept) and methods for making it.
-
OneOncology Is Early Adopter of Biosimilars in U.S.
8/8/2019
OneOncology is Committed to Cost Conscious Healthcare for Patients & Payers
-
According to a BioSpace poll, approximately 86% of life science respondents are on the verge of job burnout. Are you one of the 86%? Does this mean you need to start looking for a new job? This is definitely one of your options. Start here to look at all of the great opportunities out there in t...
-
Amgen Announces 2019 Third Quarter Dividend
8/2/2019
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the third quarter of 2019.
-
Amgen Reports Second Quarter 2019 Financial Results
7/30/2019
Amgen announced financial results for the second quarter of 2019.